Prevention of bronchopulmonary dysplasia: current strategies.
- Author:
Deepak JAIN
1
;
Eduardo BANCALARI
Author Information
1. Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
- Publication Type:Journal Article
- MeSH:
Adrenal Cortex Hormones;
therapeutic use;
Animals;
Bronchopulmonary Dysplasia;
prevention & control;
Caffeine;
therapeutic use;
Humans;
Oxygen;
therapeutic use;
Pulmonary Surfactants;
therapeutic use;
Respiration, Artificial
- From:
Chinese Journal of Contemporary Pediatrics
2017;19(8):841-851
- CountryChina
- Language:English
-
Abstract:
Bronchopulmonary dysplasia (BPD) is one of the few diseases affecting premature infants that have continued to evolve since its first description about half a century ago. The current form of BPD, a more benign and protracted respiratory failure in extremely preterm infants, is in contrast to the original presentation of severe respiratory failure with high mortality in larger premature infants. This new BPD is end result of complex interplay of various antenatal and postnatal factors causing lung injury and subsequent abnormal repair leading to altered alveolar and vascular development. The change in clinical and pathologic picture of BPD over time has resulted in new challenges in developing strategies for its prevention and management. While some of these strategies like Vitamin A supplementation, caffeine and volume targeted ventilation have stood the test of time, others like postnatal steroids are being reexamined with great interest in last few years. It is quite clear that BPD is unlikely to be eliminated unless some miraculous strategy cures prematurity. The future of BPD prevention will probably be a combination of antenatal and postnatal strategies acting on multiple pathways to minimize lung injury and abnormal repair as well as promote normal alveolar and vascular development.
